Vancomycin

Generic Name: Vancomycin

Brand Names: Firvanq, Vancocin

Drug Type: Small Molecule

Chemical Formula: C_₆₆H_₇₅Cl_₂N_₉O_₂₄

CAS Number: 1404-90-6

Unique Ingredient Identifier: 6Q205EH1VU

Background: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].

Indication: Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associated diarrhea and for enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).

Associated Conditions: Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection

Clinical Trials

Oral Vancomycin Vs Placebo in the Prevention of Recurrence of Clostridioides Difficile's Infection

Phase 3

Completed

Conditions: Clostridioides Difficile Infection

Interventions: Drug: Oral Vancomycin
Drug: Placebo

First Posted Date: 2022-04-11

Last Posted Date: 2024-12-12

Lead Sponsor: Julia Orígüen

Target Recruit Count: 24

Registration Number: NCT05320068

Locations: 🇪🇸
Rafael San Juan, Madrid, Spain

Efficacy of Diluted Betadine vs Antibiotic Installation Before Surgical Wound Closure in Prevention of Post Cardiac Surgery Wound Infection

Phase 4

Conditions: Surgical Wound Infection

Interventions: Drug: Betadine
Drug: Vancomycin

First Posted Date: 2022-03-11

Last Posted Date: 2022-03-11

Lead Sponsor: Assiut University

Target Recruit Count: 80

Registration Number: NCT05276687

Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence

Phase 3

Recruiting

Conditions: Clostridioides Difficile Infection

Interventions: Drug: Vancomycin or Fidaxomicin
Drug: oral capsulized Fecal Microbiota Transplantation

First Posted Date: 2022-03-04

Last Posted Date: 2025-02-13

Lead Sponsor: Benoit Guery

Target Recruit Count: 220

Registration Number: NCT05266807

Locations: 🇨🇭
CHUV, Lausanne, Vaud, Switzerland

Prevention of C.Difficile Infections With Oral Vancomycine in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Phase 3

Not yet recruiting

Conditions: Stem Cell Transplant Complications
Clostridium Difficile Infections

Interventions: Drug: Placebo
Drug: Vancomycin

First Posted Date: 2022-02-25

Last Posted Date: 2022-02-25

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 336

Registration Number: NCT05256693

A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia

Phase 2

Terminated

Conditions: MRSA Bacteremia

Interventions: Drug: Delpazolid
Drug: Vancomycin
Drug: Placebo of Delpazolid

First Posted Date: 2022-02-04

Last Posted Date: 2025-05-06

Lead Sponsor: LigaChem Biosciences, Inc.

Target Recruit Count: 40

Registration Number: NCT05225558

Locations: 🇰🇷
Chonnam National University Hospital, Gwangju, Korea, Republic of
🇰🇷
Chosun University Hospital, Gwangju, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of

and more 3 locations

Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement.

Phase 2

Recruiting

Conditions: Arthroplasty, Replacement, Hip
Osteoarthritis, Hip
Antibiotic Resistant Infection
Prosthetic Joint Infection

Interventions: Drug: Saline
Drug: Vancomycin + Tobramycin

First Posted Date: 2021-12-23

Last Posted Date: 2024-12-09

Lead Sponsor: University Hospital, Linkoeping

Target Recruit Count: 850

Registration Number: NCT05169229

Locations: 🇸🇪
Universitetssjukhuset Linköping, Linköping, Region Östergotland, Sweden

Staphylococcus Aureus Network Adaptive Platform Trial

Phase 4

Recruiting

Conditions: Staphylococcus Aureus Bacteremia

Interventions: Radiation: Whole body FDG PET/CT Imaging
Drug: Penicillin
Other: Effectiveness of early switch to oral antibiotics
Drug: Cefazolin
Drug: Clindamycin
Drug: Vancomycin

First Posted Date: 2021-11-30

Last Posted Date: 2024-06-05

Lead Sponsor: University of Melbourne

Target Recruit Count: 8000

Registration Number: NCT05137119

Locations: 🇦🇺
Cairns Hospital, Cairns, Queensland, Australia
🇨🇦
Hôpital Régional de Saint Jérôme, Saint-Jérôme, Quebec, Canada
🇳🇱
Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands

and more 146 locations

Early Antibiotics After Aspiration in ICU Patients

Phase 4

Terminated

Conditions: Aspiration
Aspiration Pneumonia

Interventions: Drug: Ceftriaxone
Drug: Amoxicillin clavulanic acid
Drug: Cefepime
Drug: Vancomycin
Drug: Levofloxacin

First Posted Date: 2021-10-15

Last Posted Date: 2024-11-01

Lead Sponsor: UConn Health

Target Recruit Count: 5

Registration Number: NCT05079620

Locations: 🇺🇸
UConn Health, John Dempsey Hospital, Farmington, Connecticut, United States

Bezlotoxumab Versus FMT for Multiple Recurrent CDI

Phase 4

Withdrawn

Conditions: Clostridium Infections
Clostridioides Difficile
Enterocolitis, Pseudomembranous

Interventions: Drug: Bezlotoxumab
Procedure: Fecal Microbiota Transplantation (FMT)
Drug: Vancomycin oral

First Posted Date: 2021-10-13

Last Posted Date: 2023-03-28

Lead Sponsor: Leiden University Medical Center

Registration Number: NCT05077085

Locations: 🇳🇱
Haaglanden Medical Center, Den Haag, Netherlands
🇳🇱
Amsterdam University Medical Centers, AMC, Amsterdam, Netherlands
🇳🇱
Leiden University Medical Center, Leiden, Netherlands

and more 1 locations

A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

Phase 1

Completed

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation

Interventions: Drug: Vancomycin Pre-Treatment
Drug: SER-155
Drug: Vancomycin Placebo
Drug: SER-155 Placebo

First Posted Date: 2021-08-09

Last Posted Date: 2024-10-01

Lead Sponsor: Seres Therapeutics, Inc.

Target Recruit Count: 60

Registration Number: NCT04995653

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Banner Health - MD Anderson Medical Center, Gilbert, Arizona, United States
🇺🇸
City of Hope, Duarte, California, United States

and more 10 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy